These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37821306)

  • 41. Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.
    Jacob J; Necchi A; Grivas P; Hughes M; Sanford T; Mollapour M; Shapiro O; Talal A; Sokol E; Vergilio JA; Killian J; Lin D; Williams E; Tse J; Ramkissoon S; Severson E; Hemmerich A; Ferguson N; Edgerly C; Duncan D; Huang R; Chung J; Madison R; Alexander B; Venstrom J; Reddy P; McGregor K; Elvin J; Schrock A; Danziger N; Pavlick D; Ross J; Bratslavsky G
    Urol Oncol; 2021 Oct; 39(10):731.e1-731.e15. PubMed ID: 34215504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
    Gerald T; Margulis V; Meng X; Bagrodia A; Cole S; Qin Q; Call SG; Mauer E; Lotan Y; Woldu SL
    Urol Oncol; 2023 Mar; 41(3):148.e17-148.e24. PubMed ID: 36653279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
    Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
    Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection.
    Blochin EB; Park KJ; Tickoo SK; Reuter VE; Al-Ahmadie H
    Mod Pathol; 2012 Nov; 25(11):1534-42. PubMed ID: 22766788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular profiling of head and neck squamous cell carcinoma.
    Feldman R; Gatalica Z; Knezetic J; Reddy S; Nathan CA; Javadi N; Teknos T
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1625-38. PubMed ID: 26614708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-L1 Expression in HPV-associated Versus HPV-independent Invasive Vulvar Squamous Cell Carcinoma.
    Bui CM; Medeiros F; Azimpouran M; Venturina M; Balzer B
    Int J Gynecol Pathol; 2024 Jul; 43(4):405-413. PubMed ID: 38303111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
    Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
    Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
    Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
    [No Abstract]   [Full Text] [Related]  

  • 54. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
    J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
    BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
    Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
    Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
    Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
    Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
    Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transitional cell and uncommon urothelial carcinoma of renal pelvis/ureter and bladder: low incidence of human papilloma virus.
    Wang JS; Tseng HH; Lin SL; Hsieh SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Mar; 59(3):151-7. PubMed ID: 9198289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.